Skip to main content
SpringerLink
Log in

A novel antipsychotic, perospirone, has antiserotonergic and antidopaminergic effects in human brain: findings from neuroendocrine challenge tests

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Perospirone is a new antipsychotic drug in which dopamine D2 antagonist and serotonin 5-HT2 antagonist effects have been found in animal studies. It was developed by a Japanese pharmaceutical company and launched in 2001. Perospirone’s receptor binding profile may resemble that of atypical antipsychotic drugs, but to date there has been no evidence relating to its receptor binding affinity in the human brain.

Objective

The purpose of this study was to investigate the receptor binding profile of perospirone via neuroendocrine challenge tests.

Methods

Twenty subjects (ten females and ten males) were tested on four occasions in a double-blind, cross-over design receiving: (a) placebo, (b) perospirone 4 mg, (c) paroxetine 20 mg, and (d) paroxetine 20 mg plus perospirone 4 mg, administered orally at 8.00 a.m. Plasma cortisol and prolactin levels were measured prior to administration and every hour for 6 h thereafter. In addition, psychological responses rated by visual analog scales and vital signs such as body temperature, pulse, and blood pressure were assessed in combination with blood sampling.

Results

Perospirone 4 mg increased prolactin levels significantly higher than placebo, whereas paroxetine 20 mg plus perospirone 4 mg significantly attenuated cortisol responses induced by paroxetine 20 mg.

Conclusions

The present findings suggest that perospirone has the characteristics of both D2 and 5-HT2 antagonist in the human brain. Further PET studies in the human brain are required in order to directly investigate these effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Breier A, Kirkpatrick B, Buchanan RW (1993) Clozapine attenuates meta-chlorophenylpiperazine (mCPP)-induced plasma cortisol increases in schizophrenia. Biol Psychiatry 34:492–494

    CAS  PubMed  Google Scholar 

  • Cowen PJ (1993) Serotonin receptor subtypes in depression: evidence from studies in neuroendocrine regulation. Clin Neuropharmacol 16:S7–S18

    Google Scholar 

  • Cowen PJ (1998) Neuroendocrine challenge test: what we can learn from them? In: Van der Kar LD (ed) Methods in neuroendocrinology. CRC Press, Boca Raton, pp 205–223

  • Curtis VA, Wright P, Reveley A, Kerwin R, Lucey JV (1995) Effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement. Br J Psychiatry 166:642–646

    CAS  PubMed  Google Scholar 

  • de Paulis T (2002) Perospirone: Sumitomo pharmaceuticals. Curr Opin Invest Drugs 3:121–129

    Google Scholar 

  • Hiemke C, Hartter S (2000) Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 85:11–28

    CAS  PubMed  Google Scholar 

  • Hirose A, Kato T, Ohno Y, Shimizu H, Tanaka H, Nakamura M, Katsube J (1990) Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytriptamine2 and dopamine2 antagonistic actions. Jpn J Pharmacol 53:321–329

    CAS  PubMed  Google Scholar 

  • Inanaga K, Irie S, Urae A, Urae T (1997) Phase I study of perospirone HCl (SM-9018) [in Japanese]. Kiso to Rinsho 31:2113–2157

    Google Scholar 

  • Jones H, Curtis VA, Wright PA, Lucey JV (1998) Risperidone is associated with blunting of d-fenfluramine evoked serotonergic responses in schizophrenia. Int Clin Psychopharmacol 13:199–203

    Google Scholar 

  • Jones H, Curtis VA, Wright P, Pilowsky LS, Lucey JV (2002) d-Fenfluramine-evoked serotonergic responses in olanzapine-treated schizophrenic patients. Psychiatry Res 113:41–47

    Article  CAS  PubMed  Google Scholar 

  • Kahn RS, Siever L, Davidson M, Greenwald C, Moore C (1993) Haloperidol and clozapine treatment and their effect on M-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine. Psychopharmacology 112:S90–S94

    CAS  PubMed  Google Scholar 

  • Kahn RS, Davidoson M, Siever LJ, Sevy S, Davis KL (1994) Clozapine treatment and its effect on neuroendocrine responses induced by the serotonin agonist, m-chlorophenylpiperazine. Biol Psychiatry 35:909–912

    CAS  PubMed  Google Scholar 

  • Kato T, Hirose A, Ohno Y, Shimizu H, Tanaka H, Nakamura M (1990) Binding profile of SM-9018, a novel antipsychotic candidate. Jpn J Pharmacol 54:478–481

    CAS  PubMed  Google Scholar 

  • Kojima H, Terao T, Iwakawa M, Soya A, Inoue N, Shiraishi Y, Son Y, Soeda S, Ueda N, Yoshimura R, Nakamura J (2003) Paroxetine as a 5-HT neuroendocrine probe. Psychopharmacology 167:97–102

    CAS  PubMed  Google Scholar 

  • Kudo Y, Nakajima T, Saito M, Sakai T, Otsuski S, Yamawaki S, Inanaga K, Tashiro N, Nakane Y, Ogura T (1997) Clinical evaluation of a serotonin-2 and dopamine-2 receptor antagonist (SDA), perospirone HCl on schizophrenia: a comparative double-blind study with mosapramine HCl [in Japanese]. Rinsho Hyoka 24:207–248

    Google Scholar 

  • Lemus CZ, Lieberman JA, Johns CA, Mayerhoff DI, Pollack S, Cooper TB, Novacenko H (1991) Hormonal response to fenfluramine challenges in clozapine-treated schizophrenic patients. Biol Psychiatry 29:691–694

    CAS  PubMed  Google Scholar 

  • López-Calulla C, Dominquez N (1999) Determination of paroxetine in plasma by high-performance liquid chromatography for bioequivalence studies. J Chromatogr B 724:393–398

    Google Scholar 

  • Markianos M, Hatzimanolis J, Lykouras L (2001) Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone. Psychopharmacology 157:55–59

    Article  CAS  PubMed  Google Scholar 

  • Mizuno Y, Tani N, Komuro S, Kanamaru H, Nakatsuka I (2003) In vitro metabolism of perospirone in rat, monkey and human liver microsomes.Eur J Drug Metab Pharmacokinet 28:59–65

    CAS  PubMed  Google Scholar 

  • Mohr P, Horáček J, Motlová L, Libiger J, Czobor P (1999) Effects of haloperidol treatment on prolactin response to d-fenfluramine challenge in acute schizophrenia. Psychopharmacology 141:322–325

    Google Scholar 

  • Murasaki M, Koyama T, Machiyama Y, Yagi G, Kamijima K, Kudo Y, Otsuki S, Inanaga K, Miura S (1997a) Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia: late-phase II study [in Japanese]. Kiso to Rinsho 31:2181–2206

    Google Scholar 

  • Murasaki M, Yamashita I, Machiyama Y, Yagi G, Kamijima K, Kudo Y, Otsuki S, Inanaga K, Miura S (1997b) Early phase 2 study of a new antipsychotic, perospirone HCl (SM-9018), on schizophrenia [in Japanese]. Kiso to Rinsho 31:2159–2179

    Google Scholar 

  • Murasaki M, Koyama T, Machiyama Y, Yagi G, Kamijima K, Kudo Y, Otsuki S, Inanaga K, Miura S (1997c) Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia: a study of long-term administration [in Japanese]. Kiso to Rinsho 31:2207–2230

    Google Scholar 

  • Murasaki M, Koyama T, Machiyama Y, Yagi G, Kamijima K, Toru M, Ushijima S, Miura S (1997d) Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia: a comparative double-blind study with haloperidol [in Japanese]. Rinsho Hyoka 24:159–205

    Google Scholar 

  • Ohno Y, Ishibashi T, Okada K, Ishida K, Nakamura M (1995) Effects of subchronic treatments with SM-9018, a novel 5-HT2 and D2 antagonist, on dopamine and 5-HT receptors in rats. Prog Neuropsychopharmacol Biol Psychiatry 19:1091–1101

    Article  CAS  PubMed  Google Scholar 

  • Onrust SV, McClellan K (2001) Perospirone. CNS Drugs 15:329–337

    CAS  PubMed  Google Scholar 

  • Owen RR, Gutierrez-Esteinou R, Hsiao J, Hadd K, Benkelfat C, Lawlor BA, Murphy DL, Pickar D (1993) Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia. Arch Gen Psychiatry 50:636–644

    CAS  PubMed  Google Scholar 

  • Reist C, Helmeste D, Albers L, Chhay H, Tang SW (1996) Serotonin indices and impulsivity in normal volunteers. Psychiatry Res 60:177–184

    Article  PubMed  Google Scholar 

  • Scheepers FE, Gispen de Wied CC, Kahn RS (2001) The effect of olanzapine treatment on m-chrolophenylpiperazine-induced hormone release in schizophrenia. J Clin Psychopharmacol 21:575–582

    Article  CAS  PubMed  Google Scholar 

  • Takahashi Y, Kusumi I, Ishikane T, Koyama T (1998) In vivo occupation of dopamine D1, D2, and serotonin2A receptors by novel antipsychotic drug, SM-9018 and its metabolite, in rat brain. J Neural Transm 105:181–191

    Article  CAS  PubMed  Google Scholar 

  • Yasui-Furukori N, Inoue Y, Tateishi T (2003) Determination of a new atypical antipsychotic agent perospirone and its metabolite in human plasma by automated column-switching high-performance liquid chromatography. J Chromatogr B 789:239–245

    Article  CAS  Google Scholar 

  • Yevich JP, New JS, Smith DW, Lobeck WG, Catt JD, Minielli JL, Erison MS, Taylor DP, Ribelt LA, Temple DL (1986) Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisooxazol-3-yl)piperazine derivatives as potential antipsychotic agents. J Med Chem 29:359–369

    CAS  PubMed  Google Scholar 

Download references

Acknowledgement

This research was supported partially by Sumitomo and Yoshitomi Welfide Pharmaceuticals.

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Occupational and Environmental Health School of Medicine, Yahatanishi-ku, Kitakyushu, 807-8555, Japan

    M. Iwakawa, T. Terao, A. Soya, H. Kojima, Y. Inoue, N. Ueda, R. Yoshimura & J. Nakamura

Authors
  1. M. Iwakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Terao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Soya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Kojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y. Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Yoshimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Terao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iwakawa, M., Terao, T., Soya, A. et al. A novel antipsychotic, perospirone, has antiserotonergic and antidopaminergic effects in human brain: findings from neuroendocrine challenge tests. Psychopharmacology 176, 407–411 (2004). https://doi.org/10.1007/s00213-004-1905-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-004-1905-8

Keywords

Search

Navigation